This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Brentuximab vedotin in addition to cyclophosphamide, doxorubicin, prednisolone (CHP) as intravenous infusion is in development for the treatment of CD30+ mature T-cell lymphoma also known as peripheral T cell lymphoma (PTCL), a subtype of non-Hodgkins lymphoma. PTCL is a group of aggressive and fast growing lymphomas that develop from mature white blood cells called T-cells and natural killer (NK) cells. If the lymphoma cells express a protein called CD30, it is described as CD30+. In most cases, it is not known what causes T-cell lymphoma. Symptoms vary depending the type of T-cell lymphoma and where it develops. Often, the first symptom of lymphoma is a painless swelling of a lymph node or a group of lymph nodes. Clinical outcomes out of the current standard of care for PTCL are insufficient and there are still unmet needs for a new therapy.
Brentuximab vedotin is a monoclonal antibody cancer treatment medicine that lead to cell death selectively in CD30-expressing tumour cells. Brentuximab vedotin in addition to CHP will offer an additional treatment option for patients with CD30+ mature T-cell lymphoma.

Download Full Article

Twitter

Related Posts

Daratumumab injected under the skin (subcutaneous formulation) is in development for the treatment multiple myeloma (MM) as an alternative to currently approved daratumumab intravenous formulation. MM is a rare, incurable cancer of the plasma cells in the bone marrow where large amounts of abnormal plasma cells are produced and interfere with the production of platelets, red and white blood cells. People with MM will experience periods of time without symptoms followed by periods when the illness comes back (‘relapsed’ MM). Eventually the periods without symptoms will shorten and the illness will become immune to the drugs given to treat it (‘refractory’ MM).

Lenalidomide in addition to a chemotherapy combination known as R-CHOP is in clinical development for newly diagnosed, previously untreated adult patients with diffuse large B-cell lymphoma (DLBCL) of the subtype known as activated B-cells (ABC) type. DLBCL is a cancer affecting a type of white blood cells called lymphocytes or B-cells. It is the most common form of non-Hodgkin lymphoma among adults. DLBCL is an aggressive cancer and although it can be cured in more than half of people affected, it remains a serious and life threatening disease. Treatment does not work as well for patients with the ABC type compared to patients with other DLBCL types who receive standard treatment.

Acalabrutinib is a novel oral anti‐cancer drug in clinical development for people with chronic lymphocytic leukaemia (CLL) who have not received any previous treatment. CLL is a type of cancer in which too many white blood cells are produced. As these cells develop abnormally, they are unable to function and fight infection and reduce the production of healthy blood cells. The disease is chronic and develops slowly. Treatment for CLL is complex and depends on a number of factors, including extent of disease, previous treatment, patient’s age, symptoms and general state of health. Patients whose CLL is not causing any symptoms or is getting worse only very slowly may not need treatment. Treatment for CLL is started only if symptoms become troublesome.

Acalabrutinib is a novel oral anti-cancer drug in clinical development for people with relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL) who have previously been treated (second line or greater). CLL is a type of cancer in which too many white blood cells are produced. As these cells develop abnormally, they are unable to function and fight infection and stop the production of healthy blood cells. The disease is chronic and develops slowly. R/R CLL means the cancer has come back after treatment and reaching remission, or the cancer has failed to respond to treatment. Treatment options for R/R CLL include targeted therapy drugs, chemotherapy, radiation therapy or surgery.